LUCIDITY phase 3 topline data presented at CTAD for HMTM - the only oral anti-Tau therapy in late-stage development
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities
OTE0002
TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results
* Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US …
OTE0002
Tau-targeting Alzheimer's treatment, HMTM, moving toward regulatory submission based on initial data from TauRx's LUCIDITY trial
* LUCIDITY data suggest that participants receiving hydromethylthionine mesylate (HMTM) decline at a rate substantially less than is typical in Alzheimer's based on published research
OTE0002
TauRx's late-stage clinical trial reaches new milestone
- Significant milestone in the only late-stage clinical trial targeting tau pathology of Alzheimer's
OTE0001
